New T-cell Immunotherapies Market – Future Pipeline/Clinical Trial Analysis and Revenue Forecast Overview

JERSEY CITY, NJ, June 23, 2022 /PRNewswire/ — InsightAce Analytic Pvt. announces the publication of a market assessment report on “Global market for novel T-cell immunotherapies– Industry trends, clinical trial/pipeline analysis, funding analysis, industry competition analysis, and revenue forecast to 2030.

InsightAce analytics logo

According to the latest research from InsightAce Analytic, the global market size for novel T-cell immunotherapies is expected to register a promising CAGR of 47% during the period 2022-2030.

Request for sample pages:

In T-cell immunotherapy, our own immune cells are reprogrammed to be more effective against cancer. T cell transfer therapy is an adoptive cell therapy known as adoptive immunotherapy and immune cell therapy. T cells, activated T cells, Tregs, virus-driven T cells, and T cell vaccines are examples of new T cell therapies. In clinical trials, gamma delta T cell therapies have surpassed conventional cancer therapies in terms of efficacy and specificity against cancer cells. The therapy requires a short course of treatment without aggressive chemotherapy. T-cell immunotherapy is a new and rapidly developing area of ​​oncology. Due to their high target specificity, potential for personalization, ability to generate immunological memory, and common side effects, T-cell therapies have emerged as a promising option among current targeted cancer therapies.

The growing incidence of chronic diseases will propel the development of the new T cell immunotherapies market during the forecast period. In addition, various strategic agreements between the involved therapy developers and research institutes to innovate the therapies are expected to drive the growth of the novel T cell immunotherapies market. and the increasing number of clinical trials, will provide opportunities in the years to come. Also, the government is educating the growing geriatric population and cancer patients about health. However, the high investments required for the development of the therapy, the lack of standard therapeutic protocols and the scarcity of qualified professionals limit the growth of the market.

In terms of region, the North American region is the major revenue holder of this market owing to growing awareness of cell therapies, increasing government investments in research and development of cell therapies to treat various diseases and the strong demand for new therapies. On the other hand, the Europe The region is also expected to dominate this market due to advancements in biopharmaceuticals and high prevalence of cancer. Moreover, the Asia Pacific The market is expected to grow faster due to growth in cell therapy manufacturing industries and increasing prevalence of chronic diseases.

Some of the Key Players of Novel T Cell Immunotherapies Market are Atara Biotherapeutics, AlloVir, Eureka Therapeutics, Eutilex, NexImmune, OSE Immunotherapeutics, Tevogen Bio, WindMIL Therapeutics, GammaDelta Therapeutics Limited, Acepodia, Adaptate Therapeutics, Adicet, Cytomed Therapeutics, Gadeta, IN8bio, Kiromic Biopharma, Lava Therapeutics, Takeda Pharmaceuticals, TC Biopharm , ImCheck Therapeutics, Expression Therapeutics LLC, Triumvira Immunologics, PureTech Health, PhosphoGam, Caladrius Biosciences, Eli Lilly and Company, Miltenyi Biotec, Sangamo Therapeutics (TxCell), Cellenkos Inc., Pfizer Inc., PolTREG SA., Parvus Therapeutics, ILTOO Pharma , Philogen SpA, TRACT Therapeutics, Inc., REGiMMUNE Co, Ltd., Roche, Celgene, AHEAD THERAPEUTICS SL and other important players.

Innovative therapies, partnerships, collaborations and agreements are a priority for leading manufacturers in this industry. Additionally, growing public awareness of cellular treatments will help drive the expansion of the market.

Recent key developments:

  • In May 2022, Harpoon Therapeutics announced a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq®) for use in the clinical development program. Under this agreement, Harpoon is the sponsor of the planned clinical trials and Roche will supply atezolizumab.

  • In October 2021, Takeda Pharmaceutical Company Limited announced the fiscal year of acquisition of GammaDelta Therapeutics Limited. Takeda to obtain GammaDelta’s allogeneic variable delta 1 (V1) gamma-delta (γδ) T-cell therapy platforms, including blood-derived and tissue-derived platforms and early-stage cell therapy programs , thanks to the acquisition.

  • In August 2021, Trillium Therapeutics Inc. and Pfizer Inc. announced that the two companies have entered into a binding agreement under which Pfizer will acquire Trillium. With the inclusion of next-generation investigational immunotherapies for hematological malignancies, the proposed purchase strengthens Pfizer’s position as a market leader in oncology.

  • In March 2020, AlloVir, a clinical-stage T-cell immunotherapy company, has collaborated with Baylor College of Medicine to develop virus-specific allogeneic T-cell therapy to combat COVID-19. Also in September 2020AlloVir announced FDA clearance of an Investigational New Drug (IND) application for ALVR109 (an allogeneic, ready-to-use, virus-specific T-cell therapy candidate designed to target SARS-CoV- 2) for the treatment of high-risk COVID-19 19 patients.

Curious about this latest version of the report? Inquiry Before Buying @

Market segments

Market Size (Value in Million US$) and Trend Forecast and Analysis, 2022 to 2030 based on Type of T cell therapy

  • Activated T cells

  • Viral T cells

  • Tregs

  • γδ T cells

  • T cell vaccines

  • NK T cells

Market Size (Value in Million US$) and Trend Forecast and Analysis, 2022 to 2030 based on Indication of the disease

Market Size (Value in Million US$) and Trend Forecast and Analysis, 2022 to 2030 based on Region

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

North America Novel T-cell Immunotherapies Market Revenue (USD Million) by Country, 2022-2030

Europe Novel T-cell Immunotherapies Market Revenue (USD Million) by Country, 2022-2030

  • Germany

  • France

  • Italy

  • Spain

  • Russia

  • Rest of Europe

Asia Pacific Novel T-cell Immunotherapies Market Revenue (USD Million) by Country, 2022-2030

  • India

  • China

  • Japan

  • South Korea

  • Australia & New Zealand

Latin America Novel T-cell Immunotherapies Market Revenue ($ Million) by Country, 2022-2030

  • Brazil

  • Mexico

  • Rest of Latin America

Middle East & Africa Novel T-cell Immunotherapies Market Revenue (USD Million) by Country, 2022-2030

Why buy this report:

  • Receive a comprehensive clinical trial/pipeline analysis of the global Novel T Cell Immunotherapies Market outlook

  • To receive industry insights and future trends of the global Novel T Cell Immunotherapies Market

  • To analyze the new drivers and challenges of the T cell immunotherapies market

  • To get insights on the value of Novel T Cell Immunotherapies Market Size (Million US$) forecasted till 2030

  • Major Investments, Mergers and Acquisitions in the Global Novel T Cell Immunotherapies Market Industry

For customization @

Other related reports published by InsightAce Analytics:

Global Market for CAR T-Cell Therapy for Multiple Myeloma

Global T Cell (Tregs) Regulatory Therapies Market

Global Allogeneic Cell Therapy Manufacturing Market

Global market for cell therapy in immuno-oncology

About Us:

InsightAce Analytic is a market research and consulting company that empowers clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market intelligence and competition to grow businesses. We help our clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in delivering syndicated and customized market intelligence reports with in-depth analysis with key market insights in a timely and cost effective manner.

Contact us:

InsightAce Analytics Pvt. ltd.
Such. : +1 718 593 4405
Site visit:
Follow us on LinkedIn @
Follow us on Facebook @




View original content:—future-pipelineclinical-trial-analysis-and-revenue-forecast-snapshot—exclusive – report-by-insightace-analytic-301573773.html

SOURCE InsightAce Analytics Pvt. ltd.

Irene B. Bowles